Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure

NCT07275554 · tracked via the Priya Life Science China tracker

Sponsor

Qilu Hospital of Shandong University

Phase

Observational

Started

2024-12-31

Last updated

2025-12-10

Condition(s) studied

HBV Related Acute-on-chronic Liver FailureHBV-related Liver CirrhosisHBV (Hepatitis B Virus)

Study summary

This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model. The findings are of significant importance for guiding clinical practice and improving patient prognosis. Additionally, a methylomics-based classifier model for liver failure will be developed for disease prognosis analysis and clinical assessment, with the potential to enhance the diagnostic efficiency of liver failure.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Chronic hepatitis B was persistent hepatitis B surface antigen (HBsAg) seropositivity for more than six months. Hepatitis B-related liver cirrhosis was diagnosed based on histological examination, typical features on ultrasound or radiological imaging, endoscopic findings of portal hypertension, and clinical history. Hepatitis B-related acute-on-chronic liver failure meets the diagnostic criteria of the 2018 Asia-Pacific guidelines for the diagnosis and treatment of liver failure.Laboratory tests:Jaundice: Serum total bilirubin ≥ 85 µmol/L and coagulopathy \[International Normalized Ratio (INR) ≥ 1.5 or Prothrombin Activity (PTA) \< 40%\]. Exclusion Criteria: * co-infection with other hepatitis viruses; history of hepatocellular carcinoma or other malignancies; concomitant autoimmune liver disease; or insufficient clinical data.

Primary outcome measure(s)

Analysis of Methylomic Features in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure — 48months

Trial sites (1)

Facility	City	Region	Status
Qilu Hospital of Shandong University	Jinan	Shandong	Recruiting

More Qilu Hospital of Shandong University trials in China

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer Active, not recruiting

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors Starting soon

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy Active, not recruiting

IABP for MI-VSD Patients in SCAI SHOCK Stage B Starting soon

Combined Cyclic Compression Cryotherapy and Phased Rehabilitation Training for Recovery After Knee Replacement Active, not recruiting

Other trials for the same condition

Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients Starting soon

Risk Assessment for HBV-Related Liver Cancer Recruiting

Immune Dynamics in the Natural History of Chronic HBV Infection Recruiting

Clinical Characteristics of Recompensation Active, not recruiting

Plasma Proteomics Study of End-Stage Liver Disease Patients Based on Olink Technology Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07275554 on ClinicalTrials.gov ↗ ← All trials in China